MapLight Therapeutics MPLT
NASDAQ MPLT
$9.82 +0.19 (+1.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

MapLight Therapeutics (MPLT) Gains from Sales and Divestitures (2025)

Updated

MapLight Therapeutics (MPLT) posted Gains from Sales and Divestitures of -$7,000 for FY2025, compared with -$59,000 in FY2024.

Analysis

MapLight Therapeutics (MPLT) Gains from Sales and Divestitures (2025) Analysis & Trends

  • Business Quant data shows MPLT's Gains from Sales and Divestitures at -$59,000 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 MapLight Therapeutics 446.19 Mn 446.19 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -7,000.00
API Access

MapLight Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=MPLT&period=max&api_key=YOUR_API_KEY